Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation

Alan L. Robin; Abbot F. Clark; David W. Covert; Scott Krueger; Michael V.W. Bergamini; Theresa A. Landry; Jaime E. Dickerson; Sally A. Scheib; Tony Realini; Joseph M. Defaller; Gerald D. Cagle

doi:10.1016/j.ajo.2008.07.039

Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation

Alan L. Robin, Abbot F. Clark, David W. Covert, Scott Krueger, Michael V.W. Bergamini, Theresa A. Landry, Jaime E. Dickerson, Sally A. Scheib, Tony Realini, Joseph M. Defaller, Gerald D. Cagle

School of Medicine

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Purpose: To describe the intraocular pressure (IOP)-lowering effects in eyes with open-angle glaucoma (OAG) after treatment with an anterior juxtascleral depot of anecortave acetate. Design: Prospective, interventional case series. Methods: Seven eyes of six subjects with OAG, with uncontrolled IOP while being administered one or more topical medications, received 24 mg anecortave acetate delivered by anterior juxtascleral depot. IOP was assessed at baseline and regularly after treatment for up to 24 months. Results: Mean IOP before anecortave acetate treatment was 31.3 ± 11.3 mm Hg and dropped by 9.5 ± 4.5 mm Hg (32.7% ± 16.8%) within one week after treatment. This IOP reduction was sustained through six months (8.4 ± 5.4 mm Hg [29.6% ± 12.4%]) and 12 months (9.5 ± 5.7 mm Hg [34.0% ± 15.9%]) after a single anecortave acetate treatment. The injection process was well tolerated, and no eyes experienced any injection-related or drug-related serious adverse events. Conclusions: Both the anterior juxtascleral depot of a drug and anecortave acetate may be promising candidates for IOP reduction in eyes with OAG. Additional studies are required to establish better their efficacy and safety, optimal dosing frequency, mechanism of action, and potential additivity to other IOP-lowering therapies.

Original language	English (US)
Pages (from-to)	45-50.e2
Journal	American journal of ophthalmology
Volume	147
Issue number	1
DOIs	https://doi.org/10.1016/j.ajo.2008.07.039
State	Published - Jan 2009

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ajo.2008.07.039

Cite this

Robin, A. L., Clark, A. F., Covert, D. W., Krueger, S., Bergamini, M. V. W., Landry, T. A., Dickerson, J. E., Scheib, S. A., Realini, T., Defaller, J. M., & Cagle, G. D. (2009). Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation. American journal of ophthalmology, 147(1), 45-50.e2. https://doi.org/10.1016/j.ajo.2008.07.039

Robin, AL, Clark, AF, Covert, DW, Krueger, S, Bergamini, MVW, Landry, TA, Dickerson, JE, Scheib, SA, Realini, T, Defaller, JM & Cagle, GD 2009, 'Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation', American journal of ophthalmology, vol. 147, no. 1, pp. 45-50.e2. https://doi.org/10.1016/j.ajo.2008.07.039

@article{8a1ec75a138d44dc9c39d6d750f337d6,

title = "Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation",

abstract = "Purpose: To describe the intraocular pressure (IOP)-lowering effects in eyes with open-angle glaucoma (OAG) after treatment with an anterior juxtascleral depot of anecortave acetate. Design: Prospective, interventional case series. Methods: Seven eyes of six subjects with OAG, with uncontrolled IOP while being administered one or more topical medications, received 24 mg anecortave acetate delivered by anterior juxtascleral depot. IOP was assessed at baseline and regularly after treatment for up to 24 months. Results: Mean IOP before anecortave acetate treatment was 31.3 ± 11.3 mm Hg and dropped by 9.5 ± 4.5 mm Hg (32.7% ± 16.8%) within one week after treatment. This IOP reduction was sustained through six months (8.4 ± 5.4 mm Hg [29.6% ± 12.4%]) and 12 months (9.5 ± 5.7 mm Hg [34.0% ± 15.9%]) after a single anecortave acetate treatment. The injection process was well tolerated, and no eyes experienced any injection-related or drug-related serious adverse events. Conclusions: Both the anterior juxtascleral depot of a drug and anecortave acetate may be promising candidates for IOP reduction in eyes with OAG. Additional studies are required to establish better their efficacy and safety, optimal dosing frequency, mechanism of action, and potential additivity to other IOP-lowering therapies.",

author = "Robin, {Alan L.} and Clark, {Abbot F.} and Covert, {David W.} and Scott Krueger and Bergamini, {Michael V.W.} and Landry, {Theresa A.} and Dickerson, {Jaime E.} and Scheib, {Sally A.} and Tony Realini and Defaller, {Joseph M.} and Cagle, {Gerald D.}",

year = "2009",

month = jan,

doi = "10.1016/j.ajo.2008.07.039",

language = "English (US)",

volume = "147",

pages = "45--50.e2",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

number = "1",

}

TY - JOUR

T1 - Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma

T2 - A Pilot Investigation

AU - Robin, Alan L.

AU - Clark, Abbot F.

AU - Covert, David W.

AU - Krueger, Scott

AU - Bergamini, Michael V.W.

AU - Landry, Theresa A.

AU - Dickerson, Jaime E.

AU - Scheib, Sally A.

AU - Realini, Tony

AU - Defaller, Joseph M.

AU - Cagle, Gerald D.

PY - 2009/1

Y1 - 2009/1

N2 - Purpose: To describe the intraocular pressure (IOP)-lowering effects in eyes with open-angle glaucoma (OAG) after treatment with an anterior juxtascleral depot of anecortave acetate. Design: Prospective, interventional case series. Methods: Seven eyes of six subjects with OAG, with uncontrolled IOP while being administered one or more topical medications, received 24 mg anecortave acetate delivered by anterior juxtascleral depot. IOP was assessed at baseline and regularly after treatment for up to 24 months. Results: Mean IOP before anecortave acetate treatment was 31.3 ± 11.3 mm Hg and dropped by 9.5 ± 4.5 mm Hg (32.7% ± 16.8%) within one week after treatment. This IOP reduction was sustained through six months (8.4 ± 5.4 mm Hg [29.6% ± 12.4%]) and 12 months (9.5 ± 5.7 mm Hg [34.0% ± 15.9%]) after a single anecortave acetate treatment. The injection process was well tolerated, and no eyes experienced any injection-related or drug-related serious adverse events. Conclusions: Both the anterior juxtascleral depot of a drug and anecortave acetate may be promising candidates for IOP reduction in eyes with OAG. Additional studies are required to establish better their efficacy and safety, optimal dosing frequency, mechanism of action, and potential additivity to other IOP-lowering therapies.

AB - Purpose: To describe the intraocular pressure (IOP)-lowering effects in eyes with open-angle glaucoma (OAG) after treatment with an anterior juxtascleral depot of anecortave acetate. Design: Prospective, interventional case series. Methods: Seven eyes of six subjects with OAG, with uncontrolled IOP while being administered one or more topical medications, received 24 mg anecortave acetate delivered by anterior juxtascleral depot. IOP was assessed at baseline and regularly after treatment for up to 24 months. Results: Mean IOP before anecortave acetate treatment was 31.3 ± 11.3 mm Hg and dropped by 9.5 ± 4.5 mm Hg (32.7% ± 16.8%) within one week after treatment. This IOP reduction was sustained through six months (8.4 ± 5.4 mm Hg [29.6% ± 12.4%]) and 12 months (9.5 ± 5.7 mm Hg [34.0% ± 15.9%]) after a single anecortave acetate treatment. The injection process was well tolerated, and no eyes experienced any injection-related or drug-related serious adverse events. Conclusions: Both the anterior juxtascleral depot of a drug and anecortave acetate may be promising candidates for IOP reduction in eyes with OAG. Additional studies are required to establish better their efficacy and safety, optimal dosing frequency, mechanism of action, and potential additivity to other IOP-lowering therapies.

UR - http://www.scopus.com/inward/record.url?scp=57549112594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549112594&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2008.07.039

DO - 10.1016/j.ajo.2008.07.039

M3 - Article

C2 - 18789793

AN - SCOPUS:57549112594

SN - 0002-9394

VL - 147

SP - 45-50.e2

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 1

ER -

Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this